Application of LCN2 protein in preparation of medicine for treating vascular calcification
The expression of LCN2 protein is improved through recombinant adeno-associated viruses, which solves the shortcomings of vascular calcification treatment, and effectively improves vascular calcification, providing a new treatment method.
Patent Information
- Application Number
- CN202410870119.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-01
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-01
AI Technical Summary
In the prior art, the application of LCN2 protein in the treatment of vascular calcification has not been fully explored, and when vascular calcification is caused by factors such as hypertension, diabetes, and chronic kidney disease, there is a lack of effective treatment methods.
By providing a recombinant adeno-associated virus containing a vector backbone and a gene fragment of interest, encoding an LCN2 protein, used to increase the expression level of LCN2 protein and promote fatty acid beta oxidation through exogenous LCN2 protein or recombinant adeno-associated virus transfection, thereby Improve vascular calcification.
Experiments have proved that LCN2 protein can effectively inhibit calcification of vascular smooth muscle cells, increase the intracellular ATP content, and significantly improve vascular calcification in a high-phosphorus environment, providing a new drug application prospect for the treatment of vascular calcification.
Smart Images

Figure CN118903377A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to application of LCN2 protein in preparing medicine for treating vascular calcification. Background Art
[0002] Lipocalin-2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL), is a 25kDa secretory protein and a transporter of lipophilic small molecules such as steroids, lipopolysaccharides, iron and fatty acids. LCN2 is expressed in a variety of cells and is involved in the progression of a variety of diseases. For example, LCN2 is a marker for acute kidney injury, and LCN2 is also a natural immune protein associated with acute and chronic inflammation. In addition, LCN2 also plays an important role in the occurrence, development and metastasis of various cancers. However, whether LCN2 has more application areas requires further exploration and research. Summary of the invention
[0003] The purpose of the present invention is to disclose the use of LCN2 protein in the preparation of drugs for treating vascular calcification, so as to solve one or more technical problems existing in the prior art and provide at least one beneficial option or create conditions.
[0004] The first aspect of the present invention is to provide the use of Lipocalin-2 (LCN2) protein in the preparation of a drug for treating vascular calcification.
[0005] The second aspect of the present invention is to provide a recombinant adeno-associated virus capable of increasing the expression level of LCN2 protein.
[0006] The third aspect of the present invention is to provide a method for constructing the recombinant adeno-associated virus described in the second aspect of the present invention.
[0007] The application described in the first aspect of the present invention means that the LCN2 protein can play an improving role in the face of vascular calcification caused by various reasons, so it has an application prospect in the preparation of drugs for treating vascular calcification.
[0008] In a further application embodiment, the amino acid sequence of the LCN2 protein is shown in SEQ ID No:1.
[0009] In a further application embodiment, the vascular calcification is caused by hypertension, diabetes, chronic kidney disease or atherosclerosis.
[0010] In a further application embodiment, the dosage form of the drug is one of powder, ointment, gel, drops, suppositories, tablets, granules, capsules, sprays, tablets, pills or solutions.
[0011] In a further application embodiment, the drug contains a pharmaceutically acceptable carrier, and the carrier is selected from any one of a filler, a binder, a wetting agent, a disintegrant, a lubricant, a flavoring agent, or a combination thereof.
[0012] The recombinant adeno-associated virus described in the second aspect of the present invention includes a vector backbone and a target gene segment, and the target gene segment encodes the LCN2 protein. Adeno-associated virus (AAV) is a member of the Parvoviridae family. This family member is a type of tiny, non-enveloped, icosahedral virus. The diameter of the virus particle is between 20 and 26 nm, and contains a linear single-stranded DNA genome with a size of between 4.7 and 6 kb. Minor viruses have been isolated from insects to humans. AAV virus belongs to the Dependovirus class (Dependovirus), which was originally a contaminating component found in purified adenovirus liquid, hence the name.
[0013] In some application embodiments of the second aspect of the present invention, the vector backbone has a smooth muscle-specific promoter (SM22a) and a fluorescent marker (ZsGreen).
[0014] In some application embodiments of the second aspect of the present invention, the nucleotide sequence of the target gene fragment is shown as SEQ ID No: 2.
[0015] The construction method described in the third aspect of the present invention comprises the following steps:
[0016] A) constructing a recombinant adeno-associated virus vector;
[0017] B) Adeno-associated virus packaging;
[0018] Wherein, the recombinant adeno-associated virus contains a target gene fragment.
[0019] In some application embodiments of the third aspect of the present invention, the primer sequences used to amplify the target gene fragment during step A) constructing the vector are shown as SEQ ID No: 3 and SEQ ID No: 4.
[0020] The present invention provides a new use of LCN2 protein. Experiments have shown that the expression and secretion of LCN2 protein in vascular smooth muscle cells (VSMC) are inhibited in a high-phosphorus environment. By administering exogenous LCN2 protein or transfecting VSMC with a recombinant adeno-associated virus that can highly express LCN2 protein, fatty acid β-oxidation can be promoted, thereby improving vascular calcification. Based on the experimental results, it can be known that LCN2 protein can play a role in treating vascular calcification, and therefore has good application prospects in the field of preparing related drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is a photo of Alizarin red staining of VSMC in Example 1;
[0022] Figure 2 This is the Western Blotting result of VSMC in Example 1;
[0023] Figure 3 This is a quantitative bar graph of LCN2 protein in VSMC in Example 1;
[0024] Figure 4 It is a bar graph of the ELISA test results of VSMC in Example 1;
[0025] Figure 5 This is a photograph of LCN2 protein immunohistochemistry of radial artery in Example 2;
[0026] Figure 6 This is a calcification scoring analysis diagram of the radial artery in Example 2;
[0027] Figure 7 This is an Alizarin red staining photograph of VSMC treated with LCN2 protein and high-phosphate medium in Example 3;
[0028] Figure 8 This is a bar graph showing the intracellular calcium content of VSMCs treated with LCN2 protein and high-phosphate medium in Example 3;
[0029] Fig. 9 The pictures are of protein expression of SM22α and GAPDH in VSMC treated with LCN2 protein and high-phosphate medium in Example 3;
[0030] Fig.10 This is a quantitative bar graph of SM22α protein in VSMCs treated with LCN2 protein and high-phosphate medium in Example 3;
[0031] Fig.11 is a bar graph of the LCN2 mRNA levels of VSMCs treated with LCN2 knockdown in Example 3;
[0032] Fig.12 This is a photo of Alizarin red staining of VSMCs treated with LCN2 knockdown in Example 3;
[0033] Fig.13 This is a bar graph showing the intracellular calcium content of VSMCs treated with LCN2 knockdown in Example 3;
[0034] Fig.14 This is a photo of the vascular ring stained with Alizarin red in Example 4;
[0035] Fig.15is a quantitative bar graph of Alizarin red staining of vascular rings in Example 4;
[0036] Fig.16 This is a photograph of BMP2 protein immunohistochemistry of the vascular ring in Example 4;
[0037] Fig.17 is a quantitative bar graph of BMP2 protein in the vascular ring in Example 4;
[0038] Fig.18 This is a photo of the thoracic aorta stained with alizarin red in Example 6;
[0039] Fig.19 This is a bar graph showing the results of intracellular calcium content in the aorta in Example 6;
[0040] Fig. 20 The photos are of the protein expression of α-SMA and β-actin in the aorta in Example 6;
[0041] Fig.21 is a quantitative bar graph of α-SMA protein in aorta in Example 6;
[0042] Fig. 22 This is a bar graph of differentially expressed proteins screened by proteomics analysis in Example 7;
[0043] Fig.23 This is the result diagram of protein pathway enrichment in Example 7;
[0044] Fig.24 This is a bar graph of the ATP content of the cells in Example 7. DETAILED DESCRIPTION
[0045] The following examples further illustrate the content of the present invention, but should not be construed as limiting the present invention. Without departing from the spirit and essence of the present invention, modifications and substitutions made to the methods, steps or conditions of the present invention all belong to the scope of the present invention.
[0046] Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.
[0047] The molecular biology experimental methods not specifically described in the following examples are all carried out with reference to the Molecular Cloning Experiment Guide (3rd edition) or in accordance with the kits and product instructions; the biological materials of the kits, unless otherwise specified, can be obtained from commercial channels.
[0048] The specific operation steps of Western blot, immunohistochemistry, immunofluorescence, Alizarin red staining and statistical analysis in the present invention are as follows:
[0049] Western blot: Total protein of vascular tissue / vascular smooth muscle cells was extracted with tissue lysate, and protein concentration was determined by BCA method. 20 μg protein sample was loaded, 6% or 10% polyacrylamide gel electrophoresis (SDS-PAGE), 300 mA for 3 hours, wet transfer to PVDF membrane, blocked with 5% BSA blocking solution at room temperature for 1 hour, eluted with TBST, added with primary antibodies, LCN2 (Abcam), β-actin (Cell Signaling Technology), GAPDH (Cell Signaling Technology), SM22α (Proteintech) and α-SMA (Abcam), and incubated at 4°C overnight. Wash the membrane with TBST 3 times, 10 minutes each time, incubate with corresponding secondary antibodies at room temperature for 1 hour, and wash the membrane with TBST 3 times, 10 minutes each time. Antigen-antibody complex was displayed by enhanced chemiluminescence (ECL), and protein bands were exposed by universal imaging system (ChemiD MP). Image J software was used to quantitatively analyze the target bands, and the gray value of the target band and the gray value of the internal reference protein GAPDH or β-actin were used to represent the relative expression of the target protein.
[0050] Immunohistochemistry: The tissue was fixed with 4% paraformaldehyde for 48 hours, embedded in paraffin, and sliced, dewaxed to water; boiled in sodium citrate (10mM, pH6.0) in a pressure cooker for 10 minutes; cooled to room temperature, blocked with goat serum at room temperature for 1 hour, and then incubated with LCN2 (Abcam) and BMP2 (Abcam) antibodies at 4°C overnight; washed with PBS three times for 10 minutes each time, stained with DAB, counterstained with hematoxylin, dehydrated and mounted with neutral gum; observed under a microscope and collected images.
[0051] Alizarin red staining: fix the tissue with 4% paraformaldehyde for 48 hours, embed the slices in paraffin, and dewax them to water; bake the slices in a 37°C oven for 30 minutes, and stain them with 2% alizarin red dye at room temperature for 5 minutes; rinse with running distilled water until the washing solution is basically colorless; seal the slices with neutral gum after drying; observe and collect images under a microscope.
[0052] Statistical analysis: The experimental data were expressed as mean ± SEM, and multiple groups were compared using analysis of variance (ANOVA). p < 0.05 was considered statistically significant; p < 0.05 was marked with *; p < 0.01 was marked with **; p < 0.001 was marked with ****.
[0053] The exogenous LCN2 protein used in the examples was purchased from Cloud-Clone Corp., catalog number: RPB388Ra01.
[0054] Example 1: The expression and secretion of LCN2 protein in calcified VSMCs induced by high phosphorus were inhibited.
[0055] Rat aortic VSMCs were cultured in primary culture medium and treated with 3 mM sodium dihydrogen phosphate solution for 3, 5 and 7 days, respectively. Alizarin red staining was used to evaluate the degree of cell calcification, Western Blotting was used to detect the expression of cellular LCN2 protein, and ELISA was used to detect the content of LCN2 protein in the culture medium supernatant.
[0056] Figure 1 This is the Alizarin red staining result of VSMC. From the results, it can be seen that the longer the high-phosphate culture time, the more obvious the staining effect, which means that the calcification of VSMC is more serious. Figure 2 Western Blotting results of VSMCs showed that the LCN2 protein level in VSMC cells decreased significantly after 3 and 5 days of high phosphorus treatment. Figure 3 This is the quantitative graph of LCN2 protein. Figure 2 The analysis is consistent. Figure 4 The results of ELISA showed that the content of LCN2 protein in the culture medium did not change after 3 days of high phosphorus treatment, but the content of LCN2 protein in the culture medium decreased significantly after 5 and 7 days of high phosphorus treatment. These results suggest that the expression and secretion of LCN2 protein in calcified VSMC cells caused by high phosphorus are inhibited.
[0057] Example 2: Analysis of LCN2 expression in radial artery tissue of hemodialysis patients.
[0058] Radial artery tissues were collected from 17 hemodialysis patients who underwent fistula surgery. The expression of LCN2 was detected by immunohistochemistry, and calcification scores were calculated based on the patients' lateral abdominal radiographs.
[0059] Figure 5 The results of LCN2 immunohistochemistry showed that compared with patients without vascular calcification, the expression of LCN2 in radial artery tissue of patients with calcification was significantly reduced. Figure 6 This is the correlation analysis result between LCN2 immunohistochemical quantification and calcification score. It can be seen from the results that the higher the calcification score of the patient, the lower the expression level of LCN2, and the calcification score is negatively correlated with the expression of LCN2.
[0060] Example 3: LCN2 protein can improve VSMC calcification caused by high phosphorus.
[0061] Rat aortic VSMCs were cultured in primary culture medium and calcified by high phosphorus medium. Low (20 ng / μL) and high (200 ng / μL) concentrations of LCN2 protein were given at the same time. After 7 days, the degree of cell calcification was evaluated by Alizarin red staining, the intracellular calcium content was detected by kit, and the expression of VSMC contractile phenotype protein SM22α was detected by Western Blotting.
[0062] Figure 7 This is the result of Alizarin red staining. It can be seen from the results that low concentration of LCN2 protein significantly improves VSMC calcification caused by high phosphorus, and the effect of high concentration of exogenous LCN2 protein is more significant. Figure 8 is the result of intracellular calcium content, Figure 7 The results were consistent. High phosphorus led to increased intracellular calcium content, and LCN2 protein significantly improved the increase in VSMC calcium content caused by high phosphorus. Fig. 9 The protein expression results of SM22α and GAPDH in cells are shown in Figure 2. Fig.10 The quantitative results of SM22α protein in cells showed that high phosphorus would lead to a decrease in VSMC contractile phenotype protein SM22α, while LCN2 protein could reverse the decrease of SM22α to a certain extent.
[0063] Conversely, LCN2 knockdown was achieved by transfecting VSMCs with LCN2 siRNA using liposomes, and the cells were then treated with high-phosphate medium, and the degree of calcification of the cells was assessed using Alizarin red, and the calcium content in the cells was measured. Fig.11 The level of cellular LCN2 mRNA was detected by qRT-PCR. After transfection of LCN2 siRNA, the level of cellular LCN2 mRNA decreased significantly, verifying the knockdown efficiency of siRNA. Fig.12 It showed that transfection of LCN2 siRNA aggravated calcification caused by high phosphorus. Fig.13 The results of intracellular calcium content also showed that transfection of LCN2 siRNA would lead to a further increase in intracellular calcium content.
[0064] In summary, these results confirm that LCN2 protein can improve VSMC calcification caused by high phosphorus.
[0065] Example 4: LCN2 protein protects against vascular ring calcification caused by high phosphorus.
[0066] Rat aortic vascular rings were cultured in vitro, calcification was induced by high-phosphate medium, and low concentration (200 ng / μL) and high concentration (600 ng / μL) of LCN2 protein were treated at the same time. The vascular rings were collected after 7 days, fixed with paraformaldehyde, dehydrated and embedded in sections, and the degree of calcification of the vascular rings was evaluated by Alizarin red staining. The expression of osteogenic phenotype protein BMP2 was detected by immunohistochemistry.
[0067] Fig.14 This is the result of Alizarin red staining. It can be seen from the results that high phosphorus treatment for 7 days will cause obvious calcification of the vascular ring, while low concentration of LCN2 protein significantly improves the calcification of the vascular ring caused by high phosphorus, and the improvement effect of high concentration of LCN2 protein is more significant. Fig.15 is the quantitative graph of Alizarin Red staining, and its results are similar to Fig.14 The analysis is consistent. Fig.16It showed that the expression of vascular ring BMP2 protein increased significantly after 7 days of high phosphorus treatment, and high concentration LCN2 protein interference could effectively inhibit the increase of vascular ring BMP2 protein caused by high phosphorus. Fig.17 The figure is a quantitative graph of BMP2 protein. These results indicate that LCN2 protein can protect vascular ring calcification caused by high phosphorus and inhibit the upregulation of osteogenic phenotype protein BMP2.
[0068] Example 5: Construction of a recombinant adeno-associated virus capable of increasing the expression of LCN2 protein.
[0069] A) Preparation of adeno-associated virus vector:
[0070] The pHBAAV-SM22a-3flag-T2A-ZsGreen vector (purchased from Hanheng Biotechnology (Shanghai) Co., Ltd., the nucleotide sequence is shown in SEQ ID No: 5) was selected, in which the SM22a element is a smooth muscle-specific promoter. Primers were designed for PCR amplification of the LCN2 gene, upstream primer: 3'-AGCCTTGGATCCGCCACCATGGCCCTGAGTGTCAT-5' (SEQ ID No: 3), downstream primer: 3'-AGTCGTTAATTAAACGCGTGTTGTCAATGCATTGGTCGGT-5'
[0071] (SEQ ID No: 4). The restriction endonucleases BamH I and MIu I were used to digest the vector, and the purified linearized vector was recovered by agarose gel. The target gene fragment was PCR-treated according to the designed primers, and the target gene fragment of the correct size was recovered by agarose gel. The linearized vector and the target gene fragment were incubated with HB infusion reaction. TM One-step cloning and ligation system is used for ligation; the ligation product is transformed into DH5α competent cells, the bacterial solution is plated, and cultured for 12 to 16 hours; a single clone is selected for colony verification; positive clones with correct colony verification are selected for sequencing; clone samples with correct sequencing are subjected to bacterial solution amplification and plasmid extraction and purification.
[0072] B) Recombinant AAV packaging and quality testing:
[0073] A three-plasmid adeno-associated virus system was used for the virus packaging process; the three-plasmid adeno-associated virus system included the following plasmids: a vector plasmid carrying the LCN2 gene, a pAAV-RC vector plasmid, and a pHelper vector plasmid; after the three plasmid vectors were extracted with high purity and endotoxin-free, the three plasmids were co-transfected into AAV-293 cells using Hanheng's LipofiterTM transfection reagent; the cell precipitate was collected 72 hours after transfection; the cells were disrupted to remove cell debris, and the lysis supernatant containing adeno-associated virus particles was collected; the Biomiga adeno-associated virus purification kit V1469-01 was used for purification, and the purified virus liquid was collected and stored at -80°C.
[0074] Example 6: Experiment on transfection of CKD mice with recombinant adeno-associated virus.
[0075] As renal function of patients with chronic kidney disease (CKD) progressively deteriorates, cardiovascular disease (CVD) becomes one of the main causes of death, and vascular calcification is the most common pathological manifestation. The mortality rate caused by vascular calcification accounts for about 30% of the total mortality rate of end-stage renal disease. Vascular calcification is the calcium phosphate deposition process in cardiovascular disease, which seriously endangers human health. In addition to aging, it is related to the pathological processes of many diseases such as atherosclerosis, hypertension, aortic valve stenosis, coronary artery disease, diabetes and chronic kidney disease, and is a strong predictor of cardiovascular events.
[0076] Establishment of CKD mouse vascular calcification model: Male C57BL / 6J mice weighing 25-27 g were fed with 2% high phosphorus and 0.25% adenine diet for 1 month, and then changed to 2% high phosphorus and 0.1% adenine diet for 4 months. To further promote the occurrence of vascular calcification, cholecalciferol was given by intraperitoneal injection (2×10 5 IU / kg body weight) for 3 consecutive days. The mice were killed 4 days later and the aorta and other tissues were collected.
[0077] The mice were randomly divided into three groups: a control group (CTR), a calcification model group (CKD), and a drug administration group (CKD+LCN2). The mice in the control group were fed with ordinary food and injected with a control virus through the tail vein; the mice in the calcification model group were induced to calcify according to the above method and injected with a control virus through the tail vein; the mice in the drug administration group were induced to calcify according to the above method and injected with the recombinant adeno-associated virus prepared in Example 5 through the tail vein.
[0078] The aortic tissues of the mice in the above groups were collected, and the thoracic aorta was stained with Alizarin red and tested by micro-CT to evaluate the degree of vascular calcification. Fig.18The results of alizarin red staining of the thoracic aorta show that the thoracic aorta in the CKD model group shows severe calcification, and transfection with recombinant adeno-associated virus can significantly improve vascular calcification in CKD mice. Protein was extracted from the abdominal aorta, and the calcium content was determined and Western Blotting was performed. Fig.19 As for the results of calcium content measurement, similarly, the results showed that the calcium content in the aortic tissue of CKD mice was significantly increased, while transfection with recombinant adeno-associated virus significantly reduced the calcium content in the aortic tissue. Fig. 20 The results of protein detection of α-SMA and β-actin in aortic tissue showed that the level of α-SMA protein in aortic tissue of CKD mice was significantly lower than that of control mice, while transfection with recombinant adeno-associated virus could partially reverse the decrease of α-SMA protein. Fig.21 The quantitative graph of α-SMA protein is shown in Figure 2. Fig. 20 The results were consistent with the analysis. These results verified at the animal level that overexpression of LCN2 protein can protect the blood vessels of CKD mice and prevent further calcification.
[0079] Example 7: The mechanism by which LCN2 protein improves VSMC calcification induced by high phosphorus.
[0080] In order to further explore the mechanism of action of LCN2 protein in protecting VSMC calcification, a proteomics experiment was designed to analyze the changes in VSMC cell proteins after high phosphorus and LCN2 protein treatment. The treatment was similar to Example 3. Rat aortic VSMCs were primary cultured, calcification was induced by high phosphorus medium, and 200 ng / μL of LCN2 protein was given at the same time. After 7 days, the cells were collected for proteomics analysis.
[0081] Fig. 22 Differential proteins screened for proteomics analysis. Fig.23 The results of the enrichment of protein pathways upregulated in the high phosphorus + LCN2 group compared with the high phosphorus group show that the fatty acid β-oxidation pathway is mainly activated after LCN2 protein treatment. Fatty acid β-oxidation products can enter the citric acid cycle to generate energy, so fatty acid β-oxidation is an important source of cellular energy metabolism. Therefore, we used a kit to detect the ATP content in the cells, and the results are as follows Fig.24 As shown in the results, high phosphorus caused a significant decrease in ATP content in VSMC cells, and high concentrations of LCN2 protein could significantly increase the ATP content in cells. These results suggest that LCN2 protein improves VSMC calcification caused by high phosphorus by enhancing the level of fatty acid β-oxidation in VSMC cells and promoting the production of cellular ATP.
[0082] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.
Claims
1. Application of Lipocalin-2 protein in the preparation of drugs for the treatment of vascular calcification.
2. The application according to claim 1, characterized in that: The amino acid sequence of the Lipocalin-2 protein is shown in SEQ ID No:
1.
3. The application according to claim 1, characterized in that: The vascular calcification is caused by hypertension, diabetes, chronic kidney disease or atherosclerosis.
4. The use according to claim 1, characterized in that: The dosage form of the drug is one of powder, ointment, gel, drops, suppository, lozenge, granule, capsule, spray, tablet, pill or solution.
5. The application according to claim 4, characterized in that: The drug contains a pharmaceutically acceptable carrier, and the carrier is selected from any one of a filler, a binder, a wetting agent, a disintegrant, a lubricant, a flavoring agent, or a combination thereof.
6. A recombinant adeno-associated virus, characterized in that: The invention comprises a vector skeleton and a target gene fragment, wherein the target gene fragment encodes Lipocalin-2 protein.
7. The recombinant adeno-associated virus according to claim 6, characterized in that: The vector skeleton has a smooth muscle specific promoter and a fluorescent marker.
8. The recombinant adeno-associated virus according to claim 6, characterized in that: The nucleotide sequence of the target gene fragment is shown in SEQ ID No:
2.
9. The method for constructing a recombinant adeno-associated virus according to claim 6, characterized in that: Includes steps: A) constructing a recombinant adeno-associated virus vector; B) Adeno-associated virus packaging; Wherein, the recombinant adeno-associated virus contains the target gene fragment.
10. The construction method according to claim 9, characterized in that: Step A) The primer sequences used to amplify the target gene fragment during the vector construction process are shown in SEQ ID No: 3 and SEQ ID No: 4.
Citation Information
Patent Citations
Application of cartilage oligomeric matrix protein in preparing medicine for treating vascular-calcification
CN101670097A
Compositions and method for treating kidney disease
CN110198743A
Use of neutrophil gelatinase-associated lipocalin to promote crossing of therapeutic antibodies across blood-brain barrier
CN112494647A
Non-invasive determination of likely response to lipid lowering therapies for cardiovascular disease
US20220400963A1
